Correlation between pathological response to neoadjuvant immunotherapy and long-term survival in locally advanced rectal cancer: A real-world study

Table 1 Baseline characteristics of patients in different pathological response groups, n (%)/median (interquartile rage)

Baseline characteristics	Total (n = 130)	pCR group (n = 30)	MPR group (n = 30)	Non-MPR group (n = 70)	χ2/t/Z	P value
Sex					0.582	0.747
Male	78 (60.0)	19 (63.3)	17 (56.7)	42 (60.0)
Female	52 (40.0)	11 (36.7)	13 (43.3)	28 (40.0)
Age (years)	56 (48-65)	54 (45-63)	55 (46-64)	58 (50-66)	2.135	0.344
ECOG performance status					1.852	0.396
0	89 (68.5)	23 (76.7)	21 (70.0)	45 (64.3)
1	41 (31.5)	7 (23.3)	9 (30.0)	25 (35.7)
Distance from tumor to anal verge					2.018	0.365
≤ 5 cm	53 (40.8)	11 (36.7)	10 (33.3)	32 (45.7)
> 5 cm	77 (59.2)	19 (63.3)	20 (66.7)	38 (54.3)
Maximum tumor diameter (cm)	4.5 (3.2-5.8)	3.8 (2.9-5.1)	4.2 (3.1-5.5)	4.9 (3.5-6.2)	6.842	0.033
Preoperative imaging T stage					10.258	0.006
T3	82 (63.1)	25 (83.3)	22 (73.3)	35 (50.0)
T4	48 (36.9)	5 (16.7)	8 (26.7)	35 (50.0)
Preoperative imaging N stage					12.369	0.002
N0	35 (26.9)	12 (40.0)	10 (33.3)	13 (18.6)
N1	58 (44.6)	15 (50.0)	16 (53.3)	27 (38.6)
N2	37 (28.5)	3 (10.0)	4 (13.4)	30 (42.8)
Hypertension	32 (24.6)	6 (20.0)	7 (23.3)	19 (27.1)	0.658	0.720
Diabetes mellitus	21 (16.2)	4 (13.3)	5 (16.7)	12 (17.1)	0.285	0.867
Treatment regimen					8.925	0.011
Immunotherapy monotherapy	53 (40.8)	8 (26.7)	10 (33.3)	35 (50.0)
Combination immunotherapy	77 (59.2)	22 (73.3)	20 (66.7)	35 (50.0)

ECOG: Eastern Cooperative Oncology Group; pCR: Pathological complete response; MPR: Major pathological response.